ArticleJournal of the Endocrine Society2026
Per- and polyfluoroalkyl substances and adolescent bone mineral density: assessing periods of susceptibility.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic vulnerability in endocrine disruption: bridging mechanisms, models, and environmental inequities.Clinical epigenetics · 2026Review
- Per- and polyfluoroalkyl substances and adolescent bone mineral density: assessing periods of susceptibility.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Context: Per- and polyfluoroalkyl substances (PFAS) may affect adolescent bone mineral density (BMD), but few studies have examined periods of susceptibility. Objective: To assess associations of repeated serum PFAS concentrations with early adolescent BMD. Methods: Among 218 children in a prospective pregnancy and birth cohort, we quantified serum concentrations of perfluorohexane sulfonic acid (PFHxS), perfluoroctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and perfluorononanoic acid (PFNA) at delivery (cord) and ages 3, 8, and 12 years. We measured BMD at 6 skeletal sites using dual-energy X-ray absorptiometry at age 12 years. We estimated covariate-adjusted differences and 95% confidence intervals (CIs) in BMD Results: Higher PFOA concentrations were associated with lower 1/3 distal radius BMD at every time point: delivery ( Conclusion: Serum PFOA concentrations from delivery to age 12 years were associated with lower 1/3 distal radius BMD in early adolescence, while associations of other PFAS with BMD varied by exposure assessment time point, skeletal site, and sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.